These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 17507321)

  • 1. Non-nucleoside phenotypic hypersusceptibility cut-point determination from ACTG 359.
    Haubrich RH; Jiang H; Swanstrom R; Bates M; Katzenstein D; Petch L; Fletcher CV; Fiscus SA; Gulick RM;
    HIV Clin Trials; 2007; 8(2):63-7. PubMed ID: 17507321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy with indinavir, ritonavir, and delavirdine and nucleoside reverse transcriptase inhibitors in patients with HIV/AIDS who have failed multiple antiretroviral combinations.
    Grodesky M; Acosta EP; Fujita N; Mason S; Gerber JG
    HIV Clin Trials; 2001; 2(3):193-9. PubMed ID: 11590527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis.
    Haubrich RH; Kemper CA; Hellmann NS; Keiser PH; Witt MD; Forthal DN; Leedom J; Leibowitz M; Whitcomb JM; Richman D; McCutchan JA;
    AIDS; 2002 Oct; 16(15):F33-40. PubMed ID: 12370520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotypic susceptibility and virological outcome in nucleoside-experienced patients receiving three or four antiretroviral drugs.
    Katzenstein DA; Bosch RJ; Hellmann N; Wang N; Bacheler L; Albrecht MA;
    AIDS; 2003 Apr; 17(6):821-30. PubMed ID: 12660529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy.
    Shulman N; Zolopa AR; Passaro D; Shafer RW; Huang W; Katzenstein D; Israelski DM; Hellmann N; Petropoulos C; Whitcomb J
    AIDS; 2001 Jun; 15(9):1125-32. PubMed ID: 11416714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260).
    Demeter LM; Shafer RW; Meehan PM; Holden-Wiltse J; Fischl MA; Freimuth WW; Para MF; Reichman RC
    Antimicrob Agents Chemother; 2000 Mar; 44(3):794-7. PubMed ID: 10681363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy.
    Harrigan PR; Hertogs K; Verbiest W; Larder B; Yip B; Brumme ZL; Alexander C; Tilley J; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 2003 Oct; 8(5):395-402. PubMed ID: 14640386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor.
    Freimuth WW
    Adv Exp Med Biol; 1996; 394():279-89. PubMed ID: 8815692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations and polymorphisms in NNRTI-naïve HIV-infected patients.
    Clevenbergh P; Cua E; Dam E; Durant J; Schmit JC; Boulme R; Cottalorda J; Beyou A; Schapiro JM; Clavel F; Dellamonica P
    HIV Clin Trials; 2002; 3(1):36-44. PubMed ID: 11819184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline antiretroviral drug susceptibility influences treatment response in patients receiving saquinavir-enhancing therapy.
    Middleton T; Smith D; Larder B; Law M; Birch C
    HIV Clin Trials; 2001; 2(6):445-52. PubMed ID: 11742431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors.
    Clark SA; Shulman NS; Bosch RJ; Mellors JW
    AIDS; 2006 Apr; 20(7):981-4. PubMed ID: 16603849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjects.
    Swanstrom R; Bosch RJ; Katzenstein D; Cheng H; Jiang H; Hellmann N; Haubrich R; Fiscus SA; Fletcher CV; Acosta EP; Gulick RM;
    J Infect Dis; 2004 Sep; 190(5):886-93. PubMed ID: 15295692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort.
    Tozzi V; Zaccarelli M; Narciso P; Trotta MP; Ceccherini-Silberstein F; De Longis P; D'Offizi G; Forbici F; D'Arrigo R; Boumis E; Bellagamba R; Bonfigli S; Carvelli C; Antinori A; Perno CF
    J Infect Dis; 2004 May; 189(9):1688-95. PubMed ID: 15116307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of genotypic and phenotypic changes in HIV-1-infected patients with virologic failure on an etravirine-containing regimen in the DUET-1 and DUET-2 clinical studies.
    Tambuyzer L; Vingerhoets J; Azijn H; Daems B; Nijs S; de Béthune MP; Picchio G
    AIDS Res Hum Retroviruses; 2010 Nov; 26(11):1197-205. PubMed ID: 20854144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delavirdine: a review of its use in HIV infection.
    Scott LJ; Perry CM
    Drugs; 2000 Dec; 60(6):1411-44. PubMed ID: 11152019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotypic susceptibility to didanosine is associated with antiviral activity in treatment-experienced patients with HIV-1 infection.
    Flandre P; Chappey C; Marcelin AG; Ryan K; Maa JF; Bates M; Seekins D; Bernard MC; Calvez V; Molina JM
    J Infect Dis; 2007 Feb; 195(3):392-8. PubMed ID: 17205478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.
    Bannister WP; Ruiz L; Cozzi-Lepri A; Mocroft A; Kirk O; Staszewski S; Loveday C; Karlsson A; Monforte Ad; Clotet B; Lundgren JD;
    AIDS; 2008 Jan; 22(3):367-76. PubMed ID: 18195563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the G190A substitution of HIV reverse transcriptase on phenotypic susceptibility of patient isolates to delavirdine.
    Uhlmann EJ; Tebas P; Storch GA; Powderly WG; Lie YS; Whitcomb JM; Hellmann NS; Arens MQ
    J Clin Virol; 2004 Nov; 31(3):198-203. PubMed ID: 15465412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergent HIV-1 Drug Resistance Mutations Were Not Present at Low-Frequency at Baseline in Non-Nucleoside Reverse Transcriptase Inhibitor-Treated Subjects in the STaR Study.
    Porter DP; Daeumer M; Thielen A; Chang S; Martin R; Cohen C; Miller MD; White KL
    Viruses; 2015 Dec; 7(12):6360-70. PubMed ID: 26690199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.